These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36297508)

  • 1. Alternative Methotrexate Oral Formulation: Enhanced Aqueous Solubility, Bioavailability, Photostability, and Permeability.
    Giri BR; Yang HS; Song IS; Choi HG; Cho JH; Kim DW
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of β-cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique.
    Bourkaib N; Zhou J; Yao J; Fang Z; Mezghrani O
    Drug Dev Ind Pharm; 2013 Jun; 39(6):918-27. PubMed ID: 22998295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Bioavailability and High Photostability of Methotrexate by Spray-Dried Surface-Attached Solid Dispersion with an Aqueous Medium.
    Giri BR; Kim JS; Park JH; Jin SG; Kim KS; Din FU; Choi HG; Kim DW
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33467157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel/dimethyl-β-cyclodextrin inclusion complexes: preparation,
    Giri BR; Lee J; Lim DY; Kim DW
    Drug Dev Ind Pharm; 2021 Feb; 47(2):319-328. PubMed ID: 33576707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate.
    Kim DS; Cho JH; Park JH; Kim JS; Song ES; Kwon J; Giri BR; Jin SG; Kim KS; Choi HG; Kim DW
    Int J Nanomedicine; 2019; 14():4949-4960. PubMed ID: 31308665
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving the solubility of vorinostat using cyclodextrin inclusion complexes: The physicochemical characteristics, corneal permeability and ocular pharmacokinetics of the drug after topical application.
    Yang J; Ma Y; Luo Q; Liang Z; Lu P; Song F; Zhang Z; Zhou T; Zhang J
    Eur J Pharm Sci; 2022 Jan; 168():106078. PubMed ID: 34838620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
    Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
    Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced oral bioavailability of koumine by complexation with hydroxypropyl-β-cyclodextrin: preparation, optimization,
    Hu Q; Fu X; Su Y; Wang Y; Gao S; Wang X; Xu Y; Yu C
    Drug Deliv; 2021 Dec; 28(1):2415-2426. PubMed ID: 34763595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and
    Al-Heibshy FNS; Başaran E; Öztürk N; Demirel M
    Drug Dev Ind Pharm; 2020 Sep; 46(9):1495-1506. PubMed ID: 32804005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with β-Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems.
    Manta K; Papakyriakopoulou P; Chountoulesi M; Diamantis DA; Spaneas D; Vakali V; Naziris N; Chatziathanasiadou MV; Andreadelis I; Moschovou K; Athanasiadou I; Dallas P; Rekkas DM; Demetzos C; Colombo G; Banella S; Javornik U; Plavec J; Mavromoustakos T; Tzakos AG; Valsami G
    Mol Pharm; 2020 Nov; 17(11):4241-4255. PubMed ID: 32986435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spray dried nanospheres for inclusion complexes of cefpodoxime proxetil with β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin: improved dissolution and enhanced antibacterial activity.
    Yurtdaş-Kırımlıoğlu G
    Drug Dev Ind Pharm; 2021 Aug; 47(8):1261-1278. PubMed ID: 34606394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
    Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
    Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amorphous Drug Solubility and Maximum Free Drug Concentrations in Cyclodextrin Solutions: A Quantitative Study Using NMR Diffusometry.
    Ueda K; Higashi K; Moribe K
    Mol Pharm; 2021 Jul; 18(7):2764-2776. PubMed ID: 34180226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation.
    Yousaf AM; Kim DW; Oh YK; Yong CS; Kim JO; Choi HG
    Int J Nanomedicine; 2015; 10():1819-30. PubMed ID: 25784807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.
    Patel SG; Rajput SJ
    AAPS PharmSciTech; 2009; 10(2):660-9. PubMed ID: 19459053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
    Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
    Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative oral exemestane formulation: improved dissolution and permeation.
    Yavuz B; Bilensoy E; Vural I; Sumnu M
    Int J Pharm; 2010 Oct; 398(1-2):137-45. PubMed ID: 20678561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterisation of ecdysterone/hydroxypropyl-Β-cyclodextrin inclusion complex with enhanced oral and transdermal bioavailability.
    Wang L; Li S; Cai H; Liu X; Feng T; Zhao X
    J Microencapsul; 2022 Mar; 39(2):145-155. PubMed ID: 35311602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.